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Abstract 
BACKGROUND: Tumor-infiltrating lymphocytes (TIL) in tumour stroma are considered to be involved in the 
elimination of malignant cells and prevention of metastasis formation. TIL consist of T lymphocytes including 
cytotoxic lymphocytes that are a constituent part of the effector mechanism of anti-tumour immunity and B 
lymphocytes that can form tertiary lymphoid structures (TLS). TLS has been described in several solid tumours 
and colorectal carcinoma (CRC), and the influence on the local and systemic anti-cancer response. 
AIM: This study aimed to quantify the presence of TLS in CRC patients and to determine their role in tumour 
progression. 
PATIENTS AND METHODS: The study included 103 patients with CRC who underwent surgery at the University 
Clinic of Digestive Surgery in Skopje, whose operative material was analysed at the Institute of Pathology, 
Medical Faculty in Skopje. The density of TLS was determined and correlated with the neoplasm status of local 
growth (T), positive lymph nodes, lymphatic invasion, and stage of the disease and tumour grade. 
RESULTS: The density of TLS was significantly higher in patients with higher stage, lower T status, and negative 
lymph nodes, in patients with no lymphatic invasion and with better-differentiated tumours. 
CONCLUSION: The density of TLS plays an important role in controlling the tumour growth, and it can be a 
parameter for neoplasm progression in CRC patients. The density of TLS influences the control of tumour 
progression. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Tumour stroma (cancer-associated stroma), 
as opposed to normal-tissue stroma, is a suitable 
environment for spreading of cancer and plays a key 
role in the growth and development of malignant 
neoplasms [1] [2]. It is considered that cellular-stromal 
interactions in malignant tumours play a significant 
role in the process of their progression. During this 
process, tumour cells are influenced by signals 
coming from stromal, endothelial, inflammatory and 
immune cells [3]. Inflammatory cells in tumour stroma 
have a double role; they are involved in tumour 
progression, and tumour-infiltrating lymphocytes or 
so-called tumour-associated lymphocytes (TAL), 
which are also present in the stroma of solid 
malignant tumours, are involved in the elimination of 
malignant cells and prevention of metastasis [4] [5]. 
TALs consist of T lymphocytes including cytotoxic 
lymphocytes, which are a constituent part of the 
effector mechanism of anti-tumour- immunity, and B-
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lymphocytes that can form tertiary lymphoid structures 
[5] [7]. 
Formation of tertiary lymphoid structures 
(follicles) (TLS) has been described in several solid 
tumours and colorectal carcinoma (CRC) [5]. They are 
transient accumulations of lymphoid cells that develop 
in non-lymphoid tissue in case of chronic inflammation 
of this tissue. They are built identical to lymph follicles 
of lymphoid organs, that is, lymph nodes. They 
contain B cell zone, which can form germinal centres, 
T cell zone, mature dendritic cells and high endothelial 
venules [7]. 
It is assumed that, in addition to other 
inflammatory cells, B lymphocytes play a significant 
role in the formation of inflammatory infiltrate during 
the onset of colorectal cancer (CRC) [5] [8], and TLS 
detected in tumours influence the local and systemic 
anti-cancer response [8].  
This study aimed to quantify the presence of 
TLS in CRC patients and to determine their role in 
tumour progression. 
 
 
Material and Methods 
 
The analysed patients in this study have 
clearly defined a cohort of patients with CRC, whose a 
tumour infiltrating lymphocytes along with B CD20+ 
cells were previously analysed and those results have 
already been published [9]. 
A total of 103 patients with CRC were 
included in the study. Sixty-eight (66.2%) were men 
and 35 (33.98%) women, with a mean age of 64.57 ± 
11.5 years; they all underwent surgery at the 
University Clinic of Digestive Surgery in the period 
from 2013 to 2017. The operative material was 
analysed at the Institute of Pathology in Skopje, where 
the diagnosis was confirmed, and the pTNM stage 
was determined.  
In this study we analyzed the elements of the 
TNM classification: T status (local growth of the 
tumor), the presence of positive lymph nodes (LN), 
the disease stage (according to TNM classification 
2010) [10] as well as the grade of tumor differentiation 
(G), and the density of TLS.  
TLS was detected microscopically on routine 
prepared slides. Areas of an invasive tumour front 
with a high density of TLS were chosen, and 
additional sections for immunohistochemistry were 
made.  
The TLS was defined by 
immunohistochemical staining with antibodies against 
CD4 (Dako Monoclonal Mouse Anti-Human CD4, 
Clone 4B12); CD8 (Dako Monoclonal Mouse Anti-
Human CD8, Clone C8/144B); CD20 (Dako 
Monoclonal Mouse Anti-Human CD20, Clone L26); 
and CD21 (Dako Monoclonal Mouse Anti-Human 
CD21, Clone 1F8) with a standard procedure using 
Immunoperoxidase LSAB + system.  
The number of TLS was counted in 10 
consecutive low-power fields (10 h 4) in the invasive 
front of the neoplasm. They were quantified as: 0 – no 
TLS found in 10 low-power field; + - 1 to 5 TLS found; 
++ - 6 to 10 found; +++ - > 10 TLS found in10 
consecutive low-power fields. 
To confirm the consistency of grading, the 
cases were scored independently by two 
investigators. Examples of TAL and immune cell 
staining are shown in Figure 1. 
 
Figure 1: TLS in the invasive front of CRC; A) Well-formed TLS in 
the invasive front of CRC at the right side of the microphone (10 x 
4); B) The same LS immunostained with an antibody against CD20. 
The cells around the venue are CD20+ (10 x 10) 
 
Descriptive statistical methods were used for 
statistical analysis of the data. Categorical variables 
are presented with absolute and relative numbers (%).  
 
Figure 2: TLS in the invasive front of CRC; A) CD4+ T lymphocytes 
in the periphery of the follicle (10 x 20); B) CD21+ dendritic cells in 
the centre of B zone (10 x 20) 
 
Fisher’s exact test was used for comparison 
of categorical variables. Spearman’s correlation 
coefficient was used to determine the degree of 
correlation between analysed parameters. The 
statistical program SPSS for Windows, version 19.0 
was used. 
 
Figure 3: TLS in the invasive front of CRC; A) Five TLS in one low-
power field (H.E. 10 x 40); b) CD20+ areas of TLS (CD20 10 x 4) 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1826                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
Results 
 
The presence of TLS was found in 85 
(82.52%) cases of the total of 103, whereas in 18 
(17.47%) cases TLS was not found, that is the 
inflammatory infiltrate which contained a different 
number of CD20+ lymphocytes confirmed with 
immunostainings showed no TLS organisation.  
Table 1 shows the distribution of TLS in the 
tumour of the examined patients.  
Table 1: TLS distribution in invasive tumour front in analysed 
series of 103 patients  
TLS No of patients Per cent (%) 
0 18 17.47 
+ (1-5) 43 41.74 
++ (6-10) 27 26.21 
+++ (> 10) 15 14.56 
 
For the value of p<0.0001, the statistical 
analysis showed a significant influence of a tumour 
local growth on the quantity of TLS in the infiltrative 
front of the neoplasm. Their quantity was significantly 
larger in tumours of lower T status. 
Table 2: TLS distribution about the examined parameters 
Parameter Tertiary Lymphoid Structures - TLS 
T status  0 + (1-5) ++ (6-10) +++ (>10) P value 
N N = 18 N = 43 N = 27 N = 15  
T1 
T2 
T3 
T4 
5 
7 
60 
31 
0 
0 
7 (11.67%) 
11 (35.48%) 
0 
1 (14.29%) 
25 (41.67%) 
17 (54.84%) 
0 
1 (14.29%) 
23 (38.33%) 
3 (9.68%) 
5 (100%) 
5 (71.43%) 
5 (8.33%) 
0 
<0.0001 
p (Kruskal-
Wallis test) 
 
Lymph node involvement 
No 
Yes 
56 
47 
4 (7.14%) 
14 (29.79% 
17 (30.36%) 
26 (55.32%) 
22 (39.29%) 
5 (10.64%) 
13 (23.21%) 
2 (4.26%) 
P = 
0.000011** 
p (Chi-square 
test) 
Lymphatic invasion – L1 
No 
Yes 
54 
49 
5 (9.26%) 
13 (26.53) 
13 (24.07%) 
30 (61.22%) 
22 (40.74%) 
5 (10.2%) 
14 (25.93%) 
1 (2.04%) 
P = 
0.000001** 
p (Chi-square 
test) 
Stage 
I 
II 
III 
IV 
11 
42 
44 
6 
0 
2 (4.765) 
12 (27.27%) 
4 (66.67%) 
0 
16 (38.1%) 
26 (59.09%) 
1 (16.67%) 
1 (9.09%) 
21 (50%) 
4 (9.09%) 
1 (16.67%) 
10 (90.91%) 
3 (7.14%) 
2 (4.55%) 
0 
< 0.0001 
p (Kruskal-
Wallis test) 
 
Grade of differentiation - G  
G1 
G2 
G3 
5 
83 
15 
0 
15 (18.07%) 
3 (20%) 
1 (20%) 
33 (39.76%) 
9 (60%) 
1 (20%) 
23 (27.71%) 
3 (20%) 
3 (60%) 
12 (14.46%) 
0 
0.028* 
p (Kruskal-
Wallis test) 
*p < 0.05; **p < 0.01. 
 
TLS quantity was significantly different among 
patients with or without disease spread in the regional 
lymph nodes (p = 0.000011). In patients with involved 
regional lymph nodes more often than in patients 
without lymph node metastasis, no tertiary follicles 
were found (29.79% vs 7.14%). They were also found 
to have 1 to 5 tertiary follicles (55.32% vs 30.36%).  
Patients without or with lymphatic invasion 
also showed a significant difference regarding the 
finding of tertiary lymphatic structures (p = 0 .000001).  
Patients with lymphatic invasion more often 
than those without invasion had no tertiary follicles in 
the infiltrative front of the neoplasm (26.53% vs 
9.26%). They were also more frequently found to have 
a small number of tertiary follicles, from 1 to 5 when 
compared to patients without lymphatic invasion 
(61.22% vs 24.07%).  
The finding of TLS in the infiltrative front of the 
neoplasm was significantly dependent on the spread 
of the disease (p < 0.0001). A smaller quantity of TLS 
was found in patients with colorectal carcinoma in the 
more advanced stage.  
Patients with good, moderate and poor 
tumour differentiation had a significantly different 
quantity of tertiary lymphoid structures (p = 0.028). 
The largest quantity of tertiary follicles was 
found in the group of well-differentiated tumours, that 
is, in 3/5 (60%) of patients, more than 10 tertiary 
follicles were found. In the group of moderate and 
poorly differentiated tumours, the largest 
number/percentage had from 1 to 5 tertiary follicles - 
33/83 (39.76%) and 9/15 (60%) of patients, 
respectively. 
The correlations between TLS and stage of 
the disease and tumour grade showed that the 
number of tertiary lymphoid structures had a negative, 
indirect correlation with the stage of the disease (R = -
0.635), and with the degree of differentiation (R = -
0.243). Therefore, the number of tertiary follicles was 
larger in tumours with lower stage and better 
differentiation, and vice versa. The two correlations 
were confirmed to be statistically significant: the 
association of the number of tertiary follicles with the 
staging was significant for the value of p < 0.0001, 
and with the degree of differentiation for the value of p 
< 0.05.  
 
 
Discussion 
 
Colorectal cancer (CRC) being the third most 
common malignant disease in the humans and the 
second most common cause for the lethal outcome of 
malignancies in the West European countries and 
eighth in the developing countries is a major public 
health problem [6] [9] [10] [11] [12]. Prognosis of 
colorectal cancer mostly depends on the stage of 
disease, and the TNM staging (AJCC/UICC) remains 
the most reliable prognostic indicator for patients with 
CRC [6]. It also depends on many other factors such 
as a tumour and surgery-related factors, histological, 
genetic, loss of heterozygosity at 18q, microsatellite 
instability status and molecular, protein biomarkers 
ant others factors [6] [13] [14] [15] [16]. 
During the phases of CRC progression, a 
different amount of inflammatory cells infiltrate a 
tumour, among them T and B lymphocytes, 
macrophages and mast cells [3] [6] [8]. It is 
considered that inflammatory infiltrate promotes 
tumour growth, but the immune cells may control 
cancer progression and outcome. The control of 
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immune system over tumors is based on the theory of 
3E rules i.e. 3-phase interaction between the tumor 
and host immune system: elimination (immune system 
eliminates tumour cells), equilibrium (immune system 
controls a tumour) and escape (tumour cells develop 
resistance to the immune system) [3] [17].  
There are evidences that high amount of 
tumour-infiltrating cells are more common in CRC with 
lower stage, in tumours with lower T status-local 
tumour growth, without nodal involvement and 
metastases and that CRC progression is influenced 
by inter-reaction between cancer cells and tumour 
microenvironment belonging to the patient [3] [18] [19] 
[20]. Human B cells develop in the bone marrow and 
after activation by Ag, enter primary follicles of lymph 
nodes or other lymphoid tissues where they undergo 
extensive proliferation and differentiation in plasma 
cells producing antibodies. After tumour antigens are 
recognised, it is discovered that the majority of 
patients with cancer develop tumour-specific 
antibodies [21] [22]. B cells present in a tumour 
infiltrating lymphocytes (TIL) might directly kill tumour 
cells through Ab-independent mechanisms or could 
mediate TIL effects by regulating other immune cells. 
They can promote the differentiation of Th1 and Th2 
cells, facilitate the formation of CD4+ T cells memory, 
and promote the survival and proliferation of activated 
CD8
+
 T cells [23]. 
TLS are described to occur in tumour stroma, 
and invasive tumour front in different types of cancer 
and a correlation was found between high densities of 
TLS and prolonged patient’s survival in breast cancer, 
high grade serous ovarian cancer, non-small cell lung 
cancer, and CRC [5] [23] [24]. Change in the immune 
response to host aimed at strengthening or rejection 
of tumour cells can be a solid ground for cancer 
immunotherapy and can offer an optimal anti-tumour 
response in patients with malignant tumours including 
CRC [25]. Also, published data confirm that 
chemotherapy might stimulate the immune system 
against a tumour by increasing the density of intra-
tumour lymphocytes, which is associated with a 
reduction of neoplasm and prolonged patient’s 
survival [26]. 
This study analysed the quantity of TLS 
regarding elements of the TNM system (Т, N) as well 
as regarding lymph vessels invasion and tumour 
differentiation. We found a statistically significant 
difference in the density of TLS in patients with 
different stage, with or without lymphatic invasion and 
with different grade. The density of TLS was higher in 
patients with lower stage, lower T status, without 
lymph node metastasis and in cancer patients with 
better differentiation. This finding in our series of 
analysed patients has shown that the density of TLS 
plays an important role in the control of tumour growth 
in the phase of elimination and equilibrium and that it 
can be a parameter for the progression of a neoplasm 
in CRC patients. The density of TLS influences the 
control of tumour progression. 
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